Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
Materials Today Bio · 2024-10 · 28 · 101239
DOI: 10.1016/j.mtbio.2024.101239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Today Bio, 2024-10. Verfasst von Fuxin Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jilin Provincial Natural Science Foundation, National Natural Science Foundation of China, Socialist Republic of Vietnam Ministry of Science and Technology.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) therapy, particularly PD1/PDL1 inhibition, has demonstrated success in bolstering durable responses in patients. However, the response rate remains below 30 %. In this study, we developed a polymeric bispecific antibody (BsAb) targeting PD1/PDL1 to enhance ICB therapy. Specifically, poly(L-glutamic acid) (PGLU) was conjugated with a double cyclic Fc binding peptide, Fc-III-4C, through condensation reactions between the -COOH group of PGLU and the -NH2 group of Fc-III-4C. This conjugate was then mixed with αPD1 and αPDL1 monoclonal antibodies (mAbs) in an aqueous solution. Mechanistically, the PD1/PDL1 BsAb (BsAbαPD1+αPDL1) acts as a bridge between tumor cells and CD8+ T cells, continuously activating CD8+ T cells to a greater extent. This leads to significantly suppressed tumor growth and prolonged survival in a mouse model of colon cancer compared to treatment with either a single mAb or a mixture of free mAbs. The tumor suppression rate achieved by the BsAbαPD1+αPDL1 was 90.1 %, with a corresponding survival rate of 83.3 % after 48 days. Thus, this study underscores the effectiveness of the BsAbαPD1+αPDL1 as a synchronizing T cell engager and dual ICBs, offering theoretical guidance for clinical ICB therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
- Key Laboratory of UV-Emitting Materials and Technology, Northeast Normal University, Ministry of Education, Changchun, Jilin, 130024, China.
Förderung
- Jilin Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Socialist Republic of Vietnam Ministry of Science and Technology
- People's Government of Jilin Province
- Ministry of Science and Technology of the People's Republic of China
- Chinese Academy of Sciences Youth Innovation Promotion Association
Zitieren
APA
Xue, F., Ren, X., Kong, C., Wang, J., Liu, L., Hu, J., Shen, N., & Tang, Z. (2024). Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Materials Today Bio, 28, 101239. https://doi.org/10.1016/j.mtbio.2024.101239
Vancouver
Xue F, Ren X, Kong C, Wang J, Liu L, Hu J, et al. Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Materials Today Bio. 2024;28:101239. doi:10.1016/j.mtbio.2024.101239
BibTeX
@article{Xue2024,
author = {Xue, Fuxin and Ren, Xitong and Kong, Chaoying and Wang, Jianfeng and Liu, Linlin and Hu, Junli and Shen, Na and Tang, Zhaohui},
title = {Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy},
journal = {Materials Today Bio},
year = {2024},
volume = {28},
pages = {101239},
doi = {10.1016/j.mtbio.2024.101239}
}
EUVIMED